Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-07

Clinical Trial Update: Selinexor in Advanced Liposarcoma [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of selinexor in dedifferentiated liposarcoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Dedifferentiated Liposarcoma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-12-07